News
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...
Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...
In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...
Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...
Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...
Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...
16h
WISH-TV on MSNEurope grants limited approval to Lilly's Alzheimer's drugEurope has given limited approval to Lilly's Alzheimer's drug, President Trump has announced a trade deal with the EU, Delta ...
Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.
Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...
The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...
Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the ...
EMA committee recommends approval of Eli Lilly’s donanemab in early symptomatic Alzheimer's disease: Indianapolis Monday, July 28, 2025, 13:00 Hrs [IST] Eli Lilly and Company an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results